- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Key statistics
On Thursday, Theravance Biopharma Inc (TBPH:NMQ) closed at 9.20, 12.06% above the 52 week low of 8.21 set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.51 |
---|---|
High | 9.52 |
Low | 9.15 |
Bid | 8.88 |
Offer | 9.96 |
Previous close | 9.20 |
Average volume | 461.07k |
---|---|
Shares outstanding | 48.56m |
Free float | 41.51m |
P/E (TTM) | -- |
Market cap | 446.75m USD |
EPS (TTM) | -0.9704 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼